What is Zacks Research’s Estimate for ESLA Q2 Earnings?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) – Zacks Research issued their Q2 2026 earnings estimates for shares of Estrella Immunopharma in a research report issued on Tuesday, July 14th. Zacks Research analyst D. Bautz expects that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for Estrella Immunopharma’s current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Estrella Immunopharma’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

Separately, Weiss Ratings raised Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Stock Down 3.8%

Shares of ESLA opened at $0.74 on Friday. The stock has a market cap of $31.93 million, a price-to-earnings ratio of -2.18 and a beta of 0.85. Estrella Immunopharma has a 52 week low of $0.73 and a 52 week high of $3.15. The business has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.20.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Saturday, May 16th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03.

Institutional Trading of Estrella Immunopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESLA. Quadrature Capital Ltd purchased a new position in shares of Estrella Immunopharma during the fourth quarter worth approximately $43,000. State Street Corp grew its stake in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after purchasing an additional 20,900 shares in the last quarter. XTX Topco Ltd grew its stake in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after purchasing an additional 39,099 shares in the last quarter. Marshall Wace LLP purchased a new position in Estrella Immunopharma during the 4th quarter worth $88,000. Finally, Geode Capital Management LLC increased its holdings in Estrella Immunopharma by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after purchasing an additional 8,318 shares during the period. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.